Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center,Single-arm Phase I/II Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

Next Previous
Trial Profile

A Multi-center,Single-arm Phase I/II Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GT-201 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Bone metastases; Brain metastases; Cervical cancer; Endometrial cancer; Gynaecological cancer; Liver metastases; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer
  • Focus Adverse reactions
  • Sponsors GRIT Biotechnology

Most Recent Events

  • 29 May 2025 According to a GRIT Biotechnology media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) 42nd annual meeting, which is taking place in Chicago, IL from May 30th to June 3rd.
  • 07 Feb 2025 Planned number of patients changed from 26 to 42.
  • 04 Jun 2024 Results (as of January 22, 2024, n= 7 pts) presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top